Biomaterials Executive, Arthur J. Coury, PhD, Joins InVivo Therapeutics’ Business Advisory Board

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for thetreatment of spinal cord injuries(SCI) and neurotrauma conditions, today announced that Arthur J. Coury, PhD, has joined the company as an advisor to the CEO.

Dr. Courys focus on polymeric biomaterials for medical products such as implantable devices, hydrogel-based devices and drug delivery systems will bring critical expertise to InVivo as the company awaits approval to begin human studies. Dr. Courys experience and leadership has led to FDA approval of multiple hydrogel products, and has been drawn from his positions as Senior Research Chemist at General Mills, Inc.; Director, Polymer Technology and Research Fellow at Medtronic, Inc.; Vice President, Research and Chief Scientific Officer at Focal, Inc.; Vice President, Biomaterials Research at Genzyme Corporation; and most recently, his work as a consultant.

Dr. Coury holds over fifty distinct patents and has published and presented widely in the field of biomaterials. In addition, Dr. Courys professional service to his field includes serving as Chair of the Minnesota Section of the American Chemical Society; as President for the Society for Biomaterials, USA; and as President for the American Institute for Medical and Biological Engineering (AIMBE).

His recent recognitions have included the receipt of the 2007 Innovation and Technology Development Award of the Society for Biomaterials, being named as one of 100 Notable People in the Medical Device Industry by MD&DI magazine, 2008, induction into the National Academy of Engineering, USA, 2009, recognition on the University of Delaware alumni Wall of Fame, 2010, The Man, the Myth, the Materials, a symposium in honor of Dr. Courys 70th birthday, 2010, induction as an American Chemical Society Fellow, 2011, and as recipient of the Society for Biomaterials Founders Award, 2012 and of the AIMBE Pierre Galletti award for 2012.

Said InVivo Therapeutics CEO Frank Reynolds, Biomaterials engineers with strong track records of executive leadership and success are a rarity, so adding Art Coury to our team is a real coup for InVivo. We look forward to having Art contribute right away by helping us scale up our company.

Dr. Coury holds a Ph.D. in organic chemistry and an M.B.A. from the University of Minnesota, and a B.S. in Chemistry from the University of Delaware.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visitwww.invivotherapeutics.com.

Safe Harbor Statement

Read the original post:
Biomaterials Executive, Arthur J. Coury, PhD, Joins InVivo Therapeutics’ Business Advisory Board